Business News

    Osteopore (ASX:OSX) signs on to license bioactive technology

    Article Image

    Osteopore (ASX:OSX) has signed two initial term sheets to license bioactive technology that accelerates bone and tissue regeneration.

    The technology is based on a bioactive compound that aims to speed up bone and tissue growth significantly, potentially leading to faster recovery times, fewer complications, and lower healthcare costs.

    Osteopore will also lead the first human clinical trial to evaluate the safety, efficacy, and long-term benefits of the compounds in various bone growth applications.

    The biologics market is expected to be worth $US420.5B by 2025, representing a significant opportunity for Osteopore.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa